Form D · Pharmaceuticals
Renavance Pharma, Inc.
Mill Valley, CA · CIK 0001468422
Offering snapshot reported Aug 6, 2010 · SEC filing
- Reported sold
- $100K Offering amount: $100K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 28, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 6, 2010 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Jul 15, 2009 | Initial | $500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Debt, Security to be acquired, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-146063
Offering of convertible promissory notes ("Notes"), the underlying shares of equity securities issuable upon conversion of Notes and the underlying shares of Common Stock issuable upon conversion of the equity securities.
Source: Form D, filed Aug 6, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andrew Busser | Director |
| John Donovan | Director, Executive |
| Mark Kessel | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
330 Deertrail Lane
Mill Valley, CA, 94941
Mill Valley, CA, 94941